Abstract: It has now been found that tetrahydrocortisol alone, when in solution or in the form of nanoparticles, or a combination of compounds where each affects intraocular pressure by a different mechanism of action is especially valuable for the treatment of elevated intraocular pressure and glaucoma, especially in the resistant patient. With such a combination, each compound may be present at a reduced concentration, even to a sub-therapeutic level (i.e., as little as 25% to 50% of the usual therapeutically active dose), thus decreasing or eliminating troublesome side effects while the combined effect on reducing intraocular pressure remains in the therapeutically useful range.

Abstract: According to an aspect of the invention, a case or slide-on unit suitable for containing an electronic device is disclosed. The case or slide-on unit incorporates a viewfinder housing assembly that allows a user to view an image when taking a picture with the electronic device.

Abstract: A viewfinder including a base member for removably mounting on an electronic device suitable for taking digital photographs, and an open-ended housing disposed substantially perpendicular to, and offset from the base member is disclosed. The housing includes a sighting grid disposed adjacent an open end of the open-ended housing.

Abstract: A viewfinder including a base member for removably mounting on an electronic device suitable for taking digital photographs, attachment means connected to said base member for coupling the base member to an electronic device, an open-ended housing disposed on the base member, and a sighting grid disposed adjacent an open end of the open-ended housing and method for using same is provided.

Abstract: A viewfinder including a base member for removably mounting on an electronic device suitable for taking digital photographs, attachment means connected to said base member for coupling the base member to an electronic device, an open-ended housing disposed on the base member, and a sighting grid disposed adjacent an open end of the open-ended housing and method for using same is provided.

Abstract: An ophthalmic irrigating solution containing hyaluronidase and an antioxidant is provided. The solution prevents a post-operative intraocular pressure rise when used during an ophthalmic surgical procedure, and also protects corneal endothelial cells. A method for preventing post-operative intraocular pressure increases in an eye during ophthalmic surgery involves irrigating an anterior chamber of the eye with an ophthalmic solution containing hyaluronidase and an antioxidant. Kits containing hyaluronidase and base medium solutions are also provided. The kits are designed such that the hyaluronidase and base medium solution are combined and administered together to an eye of a patient during or following an ophthalmic surgical procedure, such as cataract surgery, intraocular lens surgery, corneal transplant surgery, or glaucoma surgery. Administration of the components of the kit prevents an increase in post-operative intraocular pressure and also protects corneal endothelial cells.

Abstract: An ophthalmic irrigating solution containing hyaluronidase and an antioxidant is provided. The solution prevents a post-operative intraocular pressure rise when used during an ophthalmic surgical procedure, and also protects corneal endothelial cells. A method for preventing post-operative intraocular pressure increases in an eye during ophthalmic surgery involves irrigating an anterior chamber of the eye with an ophthalmic solution containing hyaluronidase and an antioxidant. Kits containing hyaluronidase and base medium solutions are also provided. The kits are designed such that the hyaluronidase and base medium solution are combined and administered together to an eye of a patient during or following an ophthalmic surgical procedure, such as cataract surgery, intraocular lens surgery, corneal transplant surgery, or glaucoma surgery. Administration of the components of the kit prevents an increase in post-operative intraocular pressure and also protects corneal endothelial cells.

Abstract: Several methods for preventing, minimizing, or delaying the incidence of posterior capsule opacification are provided. A first method involves chemically activating the surface of an implantable ocular device, such as an intraocular lens or a capsular tension ring, by grafting a chemical moiety onto the surface of the device, covalently attaching a non-cytotoxic inhibitor compound to the chemical moiety to produce an inhibitor implantable ocular device, and implanting this inhibitor implantable ocular device into the capsular bag of an eye of a patient during extracapsular cataract surgery. Appropriate inhibitor compounds include RGD mimetics, RGD peptides, and flavonoids. A second method involves surface modifying the exterior surface of a capsular tension ring by covalently attaching a mitotic inhibitor, preferably a conjugate of methotrexate and a bovine serum albumin, and implanting this inhibitor tension ring into the capsular bag of an eye of a patient during extracapsular cataract surgery.

Abstract: A syringe system for dispensing or injecting one or more fluids is provided. The syringe system includes a hollow body that retains cartridge(s) and/or syringe(s) each containing a fluid, such as an injectable fluid e.g., a catalyst in one cartridge and a polymer in the other. Upon use for dispensing two fluids, the syringe system mixes the two fluids immediately prior to or concurrently with the dispensing or injecting of the fluids. The syringe system can also be configured to independently dispense a single fluid or immediately dispense multiple fluids sequentially.

Abstract: It has now been found that tetrahydrocortisol alone, when in solution or in the form of nanoparticles, or a combination of compounds where each affects intraocular pressure by a different mechanism of action is especially valuable for the treatment of elevated intraocular pressure and glaucoma, especially in the resistant patient. With such a combination, each compound may be present at a reduced concentration, even to a sub-therapeutic level (i.e., as little as 25% to 50% of the usual therapeutically active dose), thus decreasing or eliminating troublesome side effects while the combined effect on reducing intraocular pressure remains in the therapeutically useful range.

Abstract: A fixture and method is provided for in vitro storage of a cornea. The fixture includes a platform having a corneal-sceral rim receiving surface, a clamp having a mating surface for the cornel-scleral rim and handles. A locking mechanism is provided to secure a donor cornea between the clamp and platform. The combination cornea, platform and clamp are placed in a storage unit having a fluid preservation media. In one embodiment, the storage unit includes a vial having an optically clear closed end and an opened end. A lid is secured to the open end of the vial and engages the handles in order to stabilize the clamped cornea within the vial.

Abstract: A corneal storage solution which maintains cell density and cell viability of corneas stored in vitro for a period of greater than four days up to about two weeks is provided. The solution contains a buffered, balanced, nutrient and electrolyte aqueous solution, at least one colloidal osmotic agent, a phenolic antioxidant compound, a non-lactate-generating substrate, a thiol-containing compound, insulin, and at least one antibiotic. A method for in vitro storage and preservation of the viability of human corneal endothelial cells for subsequent use includes the steps of removing a cornea from an eye globe and placing the cornea in the above corneal storage solution.

Abstract: Hyaluronic acid, a polymer found in the trabecular meshwork of the eye, has a polymeric structure that is broken down by the enzyme hyaluronidase. A method is provided for reducing elevated intraocular pressure in an eye of a patient, such as a patient suffering from glaucoma, by administering modified hyaluronidase to the surface of the eye as a drop, spray, ointment, sustained-release or non-sustained release unit, and allowing the hyaluronidase to remain within the anterior chamber of the eye. The hyaluronidase is modified to enhance penetration through the corneal barrier, and is administered in an amount effective to reduce an elevated intraocular pressure. The method thus reduces the elevated intraocular pressure in the eye of a glaucoma patient without undesirable side effects.

Abstract: Hyaluronic acid, a polymer found in the trabecular meshwork of the eye, has a polymeric structure that is broken down by the enzyme hyaluronidase. A method is provided for reducing elevated intraocular pressure in an eye of a patient, such as a patient suffering from glaucoma, by administering modified hyaluronidase to the surface of the eye as a drop, spray, ointment, sustained-release or non-sustained release unit, and allowing the hyaluronidase to remain within the anterior chamber of the eye. The hyaluronidase is modified to enhance penetration through the corneal barrier, and is administered in an amount effective to reduce an elevated intraocular pressure. The method thus reduces the elevated intraocular pressure in the eye of a glaucoma patient without undesirable side effects.

Abstract: Hyaluronic acid is commonly used as a spacer in eye surgeries such as cataract surgery, intraocular lens surgery, corneal transplant surgery and some types of glaucoma surgery. One common side effect of these surgical procedures is a postoperative rise in intraocular pressure which can be serious and can cause permanent loss of function of optic nerve fibers and, therefore, loss of visual field function as well as visual acuity function. Intraoperative and postoperative rises in intraocular pressure also occur in vitreous, retina and other posterior segment surgeries. Methods are provided for reducing the postoperative intraocular pressure in an eye to normal preoperative levels while maintaining the therapeutic effects of the hyaluronic acid.

Abstract: Hyaluronic acid is commonly used as a spacer in eye surgeries such as cataract surgery, intraocular lens surgery, corneal transplant surgery and some types of glaucoma surgery. One common side effect of these surgical procedures is a postoperative rise in intraocular pressure which can be serious and can cause permanent loss of function of optic nerve fibers and, therefore, loss of visual field function as well as visual acuity function. Intraoperative and postoperative rises in intraocular pressure also occur in vitreous, retina and other posterior segment surgeries. Methods are provided for reducing the postoperative intraocular pressure in an eye to normal preoperative levels while maintaining the therapeutic effects of the hyaluronic acid.

Abstract: An illumination device for mounting on the head of a user including a frame having a cross member and a pair of rearwardly extending temple members attached to opposite ends of the cross member. At least one focusable light assembly is rotatably mounted to the frame and includes a light source for emitting light. The light assembly is adjustable by the user for varying the vergence and direction of the light emitted from the light source.

Abstract: A necktie securing device for securing to a shirt front a necktie having a tail, an apron and a label, the label being attached to a rear surface of the apron, to a shirt front when the tail is disposed within an opening formed by the label and the apron, includes a first clip demountably attachable to the tail and having a first VELCRO material covered joining surface and a second clip demountably attachable to an overlapping edge of the shirt front and having a second joining surface covered by complementary VELCRO material, the second joining surface of the second clip being engageable with the first joining surface of the first clip.

Abstract: The present invention is a viewing assembly that can selectively create optical compound corrections in the images reflected from the viewing assembly. The viewing assembly includes a reflective surface coupled to a supporting body in such a manner that the reflective surface conforms to the contour of the supporting body. The contour of the supporting body is selectively altered by the viewer of the viewing assembly, thereby changing the shape of the reflective surface and creating desired optical corrections in the viewed reflected images.